5 withdrawn. 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Withdrawn 5 |
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pediatric Risk of Hypothyroidism With Iodinated Contrast Media Iohexol, Iodixanol, Iopromide - Hypothyroidism | Phase 4 | Withdrawn | GE Healthcare | 2022-03-01 | 2022-04-20 | |
| Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding Levothyroxine - Hypothyroidism | Phase 4 | Withdrawn | Jocelyne Karam | 2015-10-01 | 2021-09-22 | |
| The Role of Levothyroxine on Goiter With Atypia of Undetermined Significance Levothyroxine - Goiter | Phase 4 | Withdrawn | Sheng-Chiang Su | 2015-05-01 | 2019-08-21 | |
| The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Prostaglandin Analog, Timolol - Thyroid Eye Disease, Ocular Hypertension | Phase 4 | Withdrawn | Stanford University | 2014-06-01 | 2018-05-15 | |
| Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Botulinum Toxin Type A, Saline injection - Graves Ophthalmopathy | Phase 4 | Withdrawn | University of Toronto | 2011-01-01 | 2015-06-03 |
Graves Ophthalmopathy (2) · Hypothyroidism (2) · Glaucoma (1) · Goiter (1) · Graves Disease (1) · Ocular Hypertension (1)
Endocrine System Diseases (5) · Autoimmune Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Exophthalmos (2) · Eye Diseases (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (2) · Goiter (2) · Hyperthyroidism (2) · Immune System Diseases (2) · Orbital Diseases (2) · Graves Disease (1)
Thyroxine (2) · Bimatoprost (1) · Botulinum Toxins, Type A (1) · Iohexol (1) · Latanoprost (1) · Prostaglandins, Synthetic (1) · Sodium Chloride (1) · Timolol (1) · Travoprost (1) · iodixanol (1) · iopromide (1) · ioversol (1) · tafluprost (1)
GE Healthcare (1) · Jocelyne Karam (1) · Sheng-Chiang Su (1) · Stanford University (1) · University of Toronto (1)
United States (2) · Canada (1)
Andrea L. Kossler, M.D. (1) · Daniel B Rootman, MSc MD (1) · Jocelyne Karam, MD (1) · Nancy Tucker, MD FRCSC (1) · Paul F. Sherwin, MD, PhD (1) · Philippe Bourrinet, PharmD (1) · Sheng-Chiang Su (1) · Zuzana Jirakova Trnkova, MD, PhD (1)